ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

RecruitingOBSERVATIONAL
Enrollment

384

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

November 3, 2025

Study Completion Date

November 3, 2025

Conditions
Bladder CancerBiliary Tract CancerCervical CancerEndometrial CancerOvarian CancerPancreatic CancerColorectal CancerLung CancerOther Tumors
Trial Locations (27)

29303

RECRUITING

Research Site, Spartanburg

Unknown

NOT_YET_RECRUITING

Research Site, Vienna

RECRUITING

Research Site, Liège

NOT_YET_RECRUITING

Research Site, Olomouc

NOT_YET_RECRUITING

Research Site, Copenhagen

RECRUITING

Research Site, Caen

RECRUITING

Research Site, Lille

RECRUITING

Research Site, Marseille

RECRUITING

Research Site, Nice

RECRUITING

Research Site, Paris

RECRUITING

Research Site, Saint-Herblain

RECRUITING

Research Site, Berlin

RECRUITING

Research Site, Frankfurt

RECRUITING

Research Site, Heidelberg

RECRUITING

Research Site, W Rzburg

RECRUITING

Research Site, Meldola

RECRUITING

Research Site, Rome

RECRUITING

Research Site, Porto

NOT_YET_RECRUITING

Research Site, Barcelona

RECRUITING

Research Site, Barcelona

RECRUITING

Research Site, Madrid

NOT_YET_RECRUITING

Research Site, Madrid

RECRUITING

Research Site, Pamplona

RECRUITING

Research Site, Valencia

RECRUITING

Research Site, Leeds

RECRUITING

Research Site, London

N6A 5A5

NOT_YET_RECRUITING

Research Site, London, Ontario

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

collaborator

Iqvia Pty Ltd

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT06973161 - ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors | Biotech Hunter | Biotech Hunter